Sample Size Effi­ci­ency of 4-Period, 2-Seq, 2-Formu­la­tion Design [RSABE / ABEL]

posted by Sereng  – USA, 2022-01-28 19:37 (151 d 21:19 ago) – Posting: # 22757
Views: 682

Folks, I really appreciate the guidance from this Forum. We need to conduct a 4-Period, 2-Sequence, 2-Formulation BE study per FDA "product specific guidance" (PSG). The PSG also asks us to use the RSABE approach for properly adjusting the BE acceptance criteria based on "reference variability and comparing test and referenced product within-subject variability". Can we safely assume that conducting such a replicate study would (at least) reduce our sample size by 50% over a 2-Period, 2-Sequence, 2-Formulation BE study? If correct, and assuming no more dropouts (from the longer study), would there be any additional sample size efficiency arising from the use of the RSABE? Any help would be much appreciated! Many thanks!

Complete thread:

UA Flag
 Admin contact
22,181 posts in 4,647 threads, 1,572 registered users;
online 9 (0 registered, 9 guests [including 2 identified bots]).
Forum time: Wednesday 17:57 CEST (Europe/Vienna)

Nerds don’t just happen to dress informally.
They do it too consistently.
Consciously or not, they dress informally
as a prophylactic measure against stupidity.    Paul Graham

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz